Stipple Bio
- Biotech or pharma, therapeutic R&D
Leveraging the exciting Pointillist Platform we uncover novel cancer target binding epitopes against known or novel targets that preferentially bind to tumor but not to healthy tissue with the ability to apply our proprietary epitopes to multiple modalities including ADCs, TCE, Radiopharm
Two lead programs, one approaching development candidate and a second in lead series with many additional identified targets/epitopes available for collaboration
A-list investors include A16Z and GV among others
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}